[go: up one dir, main page]

NO20082709L - Kjemiske forbindelser - Google Patents

Kjemiske forbindelser

Info

Publication number
NO20082709L
NO20082709L NO20082709A NO20082709A NO20082709L NO 20082709 L NO20082709 L NO 20082709L NO 20082709 A NO20082709 A NO 20082709A NO 20082709 A NO20082709 A NO 20082709A NO 20082709 L NO20082709 L NO 20082709L
Authority
NO
Norway
Prior art keywords
human
methods
chemical compounds
relates
useful
Prior art date
Application number
NO20082709A
Other languages
English (en)
Inventor
Jayachandran Ezhuthachan
Paul Dermot Lyne
Brian Aquila
Timothy Pontz
Xiaolan Zheng
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20082709L publication Critical patent/NO20082709L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Oppfinnelsen angår kjemiske forbindelser med formel (I): (I) eller farmasøytisk akseptable salter derav, som har B-Raf-hemmende aktivitet og følgelig er anvendelige for deres antikreft-aktivitet og således ved metoder for behandling av menneske- eller dyrekroppen. Oppfinnelsen angår også metoder for fremstilling av nevnte kjemiske forbindelser, til farmasøytiske preparater som inneholder dem og til anvendelse av dem ved fremstilling av medikamenter som er anvendelige ved frembringelse av en antikreft-effekt hos et varmblodig dyr så som menneske.
NO20082709A 2005-12-22 2008-06-12 Kjemiske forbindelser NO20082709L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75331305P 2005-12-22 2005-12-22
PCT/GB2006/004756 WO2007071963A2 (en) 2005-12-22 2006-12-19 Quinazoline derivatives, process for their preparation and their use as anti-cancer agents

Publications (1)

Publication Number Publication Date
NO20082709L true NO20082709L (no) 2008-08-13

Family

ID=37846121

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082709A NO20082709L (no) 2005-12-22 2008-06-12 Kjemiske forbindelser

Country Status (12)

Country Link
US (1) US20080306096A1 (no)
EP (1) EP1966159A2 (no)
JP (1) JP2009520784A (no)
KR (1) KR20080079673A (no)
CN (1) CN101341133A (no)
AU (1) AU2006328194A1 (no)
BR (1) BRPI0620462A2 (no)
CA (1) CA2632929A1 (no)
IL (1) IL192009A0 (no)
NO (1) NO20082709L (no)
WO (1) WO2007071963A2 (no)
ZA (1) ZA200805247B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008120004A1 (en) * 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US9603848B2 (en) 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
JP2011513332A (ja) * 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド 癌の治療のためのｒａｆ阻害剤としてのｎ−（６−アミノピリジン−３−イル）−３−（スルホンアミド）ベンズアミド誘導体
KR20100122505A (ko) * 2008-02-29 2010-11-22 어레이 바이오파마 인크. Ｒａｆ 저해물질 화합물 및 이들의 이용 방법
WO2009111279A1 (en) * 2008-02-29 2009-09-11 Array Biopharma Inc. Pyrazole [3, 4-b] pyridine raf inhibitors
US20110003809A1 (en) * 2008-02-29 2011-01-06 Array Biopharma Inc. Imidazo [4,5-b] pyridine derivatives used as raf inhibitors
KR101713501B1 (ko) 2008-03-17 2017-03-07 암비트 바이오사이언시즈 코포레이션 Ｒａｆ 키나아제 조절제로서의 퀴나졸린 유도체 및 그의 사용방법
EP2323997B1 (en) 2008-07-31 2017-09-06 Senomyx, Inc. Processes and intermediates for making sweet taste enhancers
US8569316B2 (en) * 2009-02-17 2013-10-29 Boehringer Ingelheim International Gmbh Pyrimido [5,4-D] pyrimidine derivatives for the inhibition of tyrosine kinases
CA2784807C (en) * 2009-12-29 2021-12-14 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
EP2825533B1 (en) 2012-03-13 2016-10-19 Basf Se Fungicidal pyrimidine compounds
EP3593648B1 (en) 2012-08-06 2021-07-14 Firmenich Incorporated Sweet flavor modifier
JO3155B1 (ar) 2013-02-19 2017-09-20 Senomyx Inc معدِّل نكهة حلوة
CN103288760B (zh) * 2013-05-16 2015-02-18 苏州明锐医药科技有限公司 卡奈替尼的制备方法
CA2923101A1 (en) 2013-09-16 2015-03-19 Basf Se Fungicidal pyrimidine compounds
WO2015036059A1 (en) 2013-09-16 2015-03-19 Basf Se Fungicidal pyrimidine compounds
AU2014361798B2 (en) 2013-12-13 2020-06-11 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
CA2978518C (en) 2015-03-27 2023-11-21 Nathanael S. Gray Inhibitors of cyclin-dependent kinases
US10799503B2 (en) 2016-12-01 2020-10-13 Ignyta, Inc. Methods for the treatment of cancer
CN112703193A (zh) 2018-08-07 2021-04-23 弗门尼舍公司 5-取代的4-氨基-1H-苯并[c][1,2,6]噻二嗪2,2-二氧化物及其制剂和用途
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021247845A1 (en) * 2020-06-05 2021-12-09 Dana-Farber Cancer Institute, Inc. Quinazoline-derived hck inhibitors for use in the treatment of myd88 mutated diseases
CN112028886B (zh) * 2020-09-10 2021-07-06 四川大学华西医院 一种靶向egfr的荧光分子探针及其制备方法和应用
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
JP2994165B2 (ja) * 1992-06-26 1999-12-27 ゼネカ・リミテッド キナゾリン誘導体、その製造法および該キナゾリン誘導体を含有する抗癌作用を得るための医薬調剤
BR9914162A (pt) * 1998-10-01 2001-06-26 Astrazeneca Ab Derivado de amida, processo para preparar um derivado de amida, ou um sal farmaceuticamente aceitável ou éster clivável in vivo do mesmo, composição farmacêutica e uso de um derivado de amida, ou um sal farmaceuticamente aceitável ou éster clivável in vivo do mesmo
JP4628678B2 (ja) * 2002-03-29 2011-02-09 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 置換ベンズアゾールおよびＲａｆキナーゼ阻害剤としてのそれらの使用
KR20070028536A (ko) * 2004-06-15 2007-03-12 아스트라제네카 아베 항암제로서의 치환된 퀴나졸론
BRPI0514691A (pt) * 2004-08-31 2008-06-17 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, composição farmacêutica, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
JP2009532450A (ja) * 2006-04-05 2009-09-10 アストラゼネカ アクチボラグ 化合物

Also Published As

Publication number Publication date
EP1966159A2 (en) 2008-09-10
WO2007071963A3 (en) 2007-08-09
ZA200805247B (en) 2010-02-24
CA2632929A1 (en) 2007-06-28
KR20080079673A (ko) 2008-09-01
JP2009520784A (ja) 2009-05-28
BRPI0620462A2 (pt) 2011-11-16
US20080306096A1 (en) 2008-12-11
WO2007071963A2 (en) 2007-06-28
IL192009A0 (en) 2008-12-29
AU2006328194A1 (en) 2007-06-28
CN101341133A (zh) 2009-01-07

Similar Documents

Publication Publication Date Title
NO20082709L (no) Kjemiske forbindelser
NO20073719L (no) Kjemiske forbindelser
NO20070199L (no) Substituerte kinazoloner som anti-kreftmidler
NO20091683L (no) Kjemiske forbindelser
NO20071776L (no) Kinoksaliner som B RAF inhibitorer.
NO20070566L (no) Azin-karboksamider som antikreftmiddel
NO20072784L (no) Pyridenkarboksamidderivater for anvendelse som anticancer midler
NO20071246L (no) Kinazolinonderivater og deres anvendelse som B-RAF-inhibitorer.
NO20084202L (no) 4-anilinoquinolin-3-carboksamider som CSF-1R kinase inhibitorer
NO20071245L (no) Kinazolinonderivater og deres anvendelse som b-RAF-inhibitorer.
NO20082690L (no) Kjemiske forbindelser
NO20082124L (no) Bifenyloksyeddiksyrederivater for behandling av respiratorisk sykdom
NO20081729L (no) Nye diazaspiroalkaner og deres anvendelse for behandling av CCR8-medierte sykdommer
NO20061743L (no) Kinazolinderivater
WO2007113558A3 (en) Quinazolinone derivatives having b-raf inhibitory activity
NO20091703L (no) Heterocykliske sylfonamider med EDG-I antagonistisk aktivitet
WO2006067445A3 (en) Csf-1r kinase inhibitors
NO20083905L (no) Nye pyron-indol derivater og fremgangsmate for deres fremstilling
NO20085218L (no) Nye pyridinanaloger
NO20076675L (no) Aminopiperidinquinoliner og deres azaisosteriske analoger med antibakteriell aktivitet
NO20070655L (no) 2,4,6-Trisubstituerte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse ved behandling av kreft
TW200736234A (en) Chemical compounds
NO20085176L (no) Fenyl substituerte heteroaryl-derivater og andvendelse som anti-tumor agenter
WO2008145688A3 (en) Pyrrolopyridine compounds, process for their preparation, and their use as medicaments
NO20081844L (no) Terapeutiske forbindelser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application